Pfizer
Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
18 Mar 2025
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
11 Mar 2025
NEW HAVEN, Conn. and NEW YORK, March 11, 2025 – Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
13 Feb 2025
TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with metastatic
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
12 Feb 2025
Approval is based on positive data from the Phase 3 ECHELON-3 trial, which demonstrated ADCETRIS regimen reduced the risk of death by 37%, a statistically significant, clinically meaningful improvemen
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
11 Feb 2025
Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment of l
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
03 Feb 2025
BRAFTOVI in combination with cetuximab and mFOLFOX6 showed statistically significant and clinically meaningful improvement in progression-free survival and overall survival in patients with metastatic
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
31 Jan 2025
More than 20 abstracts span Pfizer’s leading genitourinary cancer portfolio of approved standards of care and growing pipeline across prostate and bladder cancers Detailed overall survival (OS) result
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
31 Jan 2025
Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer’s BRAFTOVI combination regimen compared to 40% with invest
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
10 Jan 2025
C linically meaningful and statistically significant results are the first pivotal Phase 3 data for sasanlimab, a subcutaneously administered PD-1 inhibitor If approved, sasanlimab would be the first
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
21 Dec 2024
BRAFTOVI in combination with cetuximab and mFOLFOX6 is the first and only combination regimen with targeted therapy approved for use as early as first-line for patients with metastatic colorectal canc
Featured
The history of safety glass
By Kiron Kasbekar | 26 Mar 2025
You probably already knew that the world’s VIPs move around in cars with bullet-proof glass windscreen and windows. But did you know that ‘bulletproof glass’ is not really bulletproof?
German silver: used in cutlery, music, electricals - but it’s not silver
By Kiron Kasbekar | 20 Mar 2025
This material, which was first developed in China, not Germany, and is an alloy of copper, nickel and zinc, has lost its sheen in home uses, but finds favor in electrical engineering.
Pioneers – the Wrights and Glenn Curtiss launched the aircraft industry
By Kiron Kasbekar | 17 Mar 2025
First Orville and Wilbur Wright flew their plane, the ‘Wright Flyer’, from near a small town called Kitty Hawk. Then Glenn Curtiss built planes with a very different system of controls, which has lasted until now.
What do aircraft have in common with bicycles and motorcycles?
By Kiron Kasbekar | 17 Mar 2025
From chains and sprockets to direct drives—If someone asked you what aircraft have in common with bicycles and motorcycles, how would you respond?
Radar’s ancestors: From sound mirrors to modern detection technology
By Kiron Kasbekar | 11 Mar 2025
Radar has become a well-settled technology today, especially in the field of navigation.
Nokia Bell Labs: innovations in communication, computing, technology
By Omar Almeida | 08 Mar 2025
Bell Laboratories, or Bell labs, which has now become Nokia Bell Labs, is one of the most renowned research and development organizations in the history of science and technology.
Company story – Quaker Oats
By Kiron Kasbekar | 08 Mar 2024
Quaker Oats is a company whose products I remember from my childhood days. Years before a foreign exchange crisis caused the Indian government to impose curbs on consumer product imports, we used to see a host of foreign brands in the Indian market. Including Quaker Oats, which I remember eating when I was a child, and which has been available for the past two decades or more.
How Quaker Oats grabbed customers’ attention
By Kiron Kasbekar | 07 Mar 2024
Quaker Oats, the American food products giant that was created in 1901 through the merger of many older oat millers, and was acquired by a bigger foods giant, Pepsi, in 2001, has been an innovative company. One example of its innovativeness shows in its packaging – the cereal box it launched in 1915.
Company story – Cunard Line
By Kiron Kasbekar | 12 Jan 2024
The Cunard Line started its life in Glasgow in 1839 as the British and North American Royal Mail Steam-Packet Company when Samuel Cunard was awarded the first British transatlantic steamship mail contract.
